In8Bio (INAB) Capital Expenditures (2020 - 2026)

In8Bio has disclosed Capital Expenditures across 7 years of filings, most recently posting $259000.0 for Q2 2026.

• In Q2 2026, Capital Expenditures changed N/A year-over-year to $259000.0; the TTM figure through Jun 2026 stood at $113000.0 (up 242.42% YoY), while the FY2025 annual figure was -$129000.0, down 224.04% from the prior year.
• Capital Expenditures came in at $259000.0 for Q2 2026 at In8Bio, up from -$17000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $3.6 million in Q4 2022 to a low of -$106000.0 in Q3 2025.
• Average Capital Expenditures over 5 years is $307928.6, with a median of $20500.0 recorded in 2022.
• Year-over-year, Capital Expenditures soared 4537.5% in 2023 and slumped 169.7% in 2025.
• Over 5 years, Capital Expenditures stood at $3.6 million in 2022, then plunged by 100.06% to -$2000.0 in 2023, then soared by 1750.0% to $33000.0 in 2024, then tumbled by 169.7% to -$23000.0 in 2025, then surged by 1226.09% to $259000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $259000.0 in Q2 2026, -$17000.0 in Q1 2026, and -$23000.0 in Q4 2025.